Emactuzumab

Multiple biotech companies announced significant financing rounds to advance various medical technologies and treatments, including Seaport Therapeutics' $225 million Series B for Glyph platform advancements, Alentis Therapeutics' $181.4 million Series D for ADCs targeting CLDN1, Alpha-9's $175 million Series C for targeted radiopharmaceuticals, Axonis Therapeutics' $115 million Series A for epilepsy and pain treatment, Evommune's $115 million Series C for chronic urticaria and atopic dermatitis, Trace Neuroscience's $101 million Series A for neurodegenerative disease treatments, Kivu Bioscience's $92 million Series A for ADC programs, SynOx's $92 million Series B for TGCT treatment, Agomab Therapeutics' $89 million Series D for Crohn’s disease, TRex Bio's $84 million Series B for atopic dermatitis and ulcerative colitis, Pathos AI's $62 million Series C for AI-powered drug development, ATB Therapeutics' $56.9 million Series A for antibody platform expansion, INBRAIN Neuroelectronics' $50 million Series B for BCI-Tx platform, PrognomiQ's $34 million Series D for lung cancer early detection, Archon Biosciences' $20 million seed funding for computational protein design, Passkey Therapeutics' $20 million seed funding for rare protein combinations, Zucara Therapeutics' $20 million Series B for hypoglycemia prevention, Alimetry's $18 million Series A for gut health monitoring, Sonavex's $15 million Series A for AV fistula maturation assessments, Citizen Health's $14.5 million seed funding for rare disease care, Aralez Bio's $12 million Series A for noncanonical amino acid manufacturing, Ikarovec's $10.3 million seed funding for sight loss therapy, CrossBridge Bio's $10 million seed financing for ADC therapies, Biometry's $5 million seed funding for asthma and COPD care, Ataraxis AI's $4 million seed funding for AI-native cancer diagnostic tests, and Amplified Sciences' $2.6 million seed funding for transformative diagnostics platform.

Merck KGaA's pimicotinib, a CSF-1R inhibitor, achieved a 54% objective response rate in a phase 3 trial for tenosynovial giant cell tumour (TGCT), outperforming Daiichi Sankyo's Turalio and potentially Ono's vimseltinib. The drug showed efficacy in reducing joint stiffness and pain, with Merck now planning to register it as the first systemic therapy for TGCT in China.

FDA's regulatory changes benefit cell and gene therapy companies; Tharimmune's TH-104 receives positive EMA feedback; Lexeo's LX-1001 shows interim positive results in Alzheimer's; Biogen and Neomorph partner for $1.45B in molecular glue degraders; Synox extends series B by $17M for emactuzumab; Shionogi's ensitrelvir reduces COVID-19 risk post-exposure.

SynOx Therapeutics raises $92M in Series B extension led by Gilde Healthcare for Phase 3 TANGENT trial of emactuzumab, a CSF-1R targeted antibody for Tenosynovial Giant Cell Tumour (TGCT). First patients dosed in TANGENT study, a global, multi-centre, randomized, double-blind, placebo-controlled trial evaluating emactuzumab's efficacy and safety in TGCT patients.

SynOx Therapeutics raises $92M in Series B extension led by Gilde Healthcare, supporting Phase 3 TANGENT trial of emactuzumab for Tenosynovial Giant Cell Tumour (TGCT). First patients dosed in TANGENT study, a global, multi-centre, randomized, double-blind, placebo-controlled trial evaluating emactuzumab's efficacy and safety. Emactuzumab, a CSF-1R inhibiting antibody, showed high efficacy and rapid onset in earlier TGCT clinical work.